Please assess the completion status of the following clinical trial:

Trial Title: GTX-RT in Borderline Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is borderline resectable disease. Borderline resectable lesions are defined as:~  * circumferential tumor abutment with the superior mesenteric vein (SMV) or portal vein (PV) or SMV/PV confluence over \</= 180°~ * circumferential tumor abutment with the superior mesenteric artery (SMA) over \</= 180°~ * Short segment encasement (360°) of the PV or SMV that is amenable to partial vein resection and reconstruction~ * encasement of the gastroduodenal artery up to the origin of the hepatic artery~* Patients must have measurable disease~* No previous chemotherapy or radiation to the pancreas~* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2 (Karnofsky \>/= 60%)~* Patients must have normal organ and marrow function as defined below:~  * leukocytes \>/= 3,000/μL~ * absolute neutrophil count \>/= 1,000/ μL~ * platelets \>/= 100,000/ μL~ * creatinine within normal institutional limits (ULN)~ * total bilirubin will allow for 2x the upper limit of the institution. Patients may have biliary stents or drains to lower total bilirubin to this range.~* Has a negative serum or urine pregnancy test within 7 days prior to initiation of therapy (female patients of childbearing potential). Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Patients will agree to continue contraception for 30 days from the date of the last study drug administration.~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients with metastatic disease are ineligible.~* Patients who have had prior chemotherapy for pancreatic adenocarcinoma~* Patients who have received prior radiation to an abdominal site are not eligible.~* Patients with peripheral neuropathy \>/= grade 2~* Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel), other drugs formulated with polysorbate 80, gemcitabine, or capecitabine~* Patients may not be receiving any other investigational agents.~* ECOG Performance Status 3-4~* Pregnant or breast-feeding women are excluded from this study because gemcitabine,capecitabine, and docetaxel are Class D agents with the potential for teratogenic or abortifacient effects.~* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients must not have any comorbid inflammatory conditions of the bowel such as Crohn's Disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy Followed by Radiation Treatment (Type: EXPERIMENTAL): Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m\^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m\^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m\^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).~After radiation, participants will be re-evaluated for surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).